drugset / Trial / NCT00976131

Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

NCT00976131

Phase 1 Completed 7 enrolled Columbia University
RandomizedCrossoverTriple-blindSupportive care

Summary

This research study hopes to examine the effects of Coenzyme Q10 on doxorubicin (Adriamycin) metabolism during breast cancer treatment.

Timeline

Start
2009-09
Primary completion
2012-09-30
Completion
2021-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme Q10 Other / unclassified 300 mg Oral
Subject Coenzyme Q10 Other / unclassified 600 mg Oral
Subject Coenzyme Q10 Other / unclassified 1200 mg Oral
Subject Doxorubicin Other / unclassified
Background Cyclophosphamide Other / unclassified

Indications